Testing SHR-A2102 for advanced gynecological cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced gynecological cancer (recurrent or spread) that has not responded to standard treatments.
- You must be well enough to be up and about (Eastern Cooperative Oncology Group performance status 0 or 1).
- You have at least one tumor that can be measured on a scan (like CT or MRI).
- You have not taken a similar type of targeted therapy called an antibody-drug conjugate with a topoisomerase I inhibitor (for example, trastuzumab deruxtecan or sacituzumab govitecan).
- Your major organs (like liver, kidneys, and bone marrow) are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
This Phase 2 trial tests SHR-A1811, a cancer medicine, in people with advanced or returning cervical, ovarian, or endometrial cancer. It may help shrink tumors, depending on whether you meet study safety and eligibility requirements.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
Hear when a new Advanced Gynecological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.